This Phase II trial evaluated the antitumor activity, safety, and biomarkers of camrelizumab plus apatinib and S-1 and oxaliplatin followed by treatment with camrelizumab plus apatinib, as a first-line treatment in patients with alpha-fetoprotein-producing gastric or gastro-esophageal junction adenocarcinoma.
[Signal Transduction and Targeted Therapy]
